Abstract
Abstract
Background: Transfusion services are aimed to provide only those components which patients require and keep the rest for others. Plateletpheresis is a technique performed on donors where platelet is separated ex vivo and remainder of the blood is returned to the donor. Platelet transfusion is critical due to lack of alternative; and therefore should be used rationally.
Aim: Present study is designed to evaluate Plateletpheresis procedure and uses of Single Donor Platelets (SDP) at our institute.
Materials and Methods: A 5 years study was carried out from 1st January 2012 to 31st December 2016 at a tertiary care centre where 1120 Plateletpheresis were conducted to prepare Single Donor Platelets (SDP) and transfused to 768 patients. Data were collected, compiled and compared statistically by frequency distribution and percentage proportion. Chi-square (χ2) test was applied to know the statistically significant difference (p value) of the data.
Results: An 1120 SDP were transfused to 768 patients with an average of 1.46 transfusions/ patient. An average age of donors was 32.30± SD6.84 years and Male: female ratio was 98.4:1.6. The average pre and post donation platelets/cumm of donors was 289.96x103± SD13.9x103 and 244.86x103± SD10.5x103 respectively and an average yield of SDP was 3.20x1011± SD1.86. Out of 1120 SDP transfusions given, clinically belonged to; dengue 64.1%, malaria 9.0%, malignancy 7.9%, thrombocytopenia due to unknown cause 5.0%, aplastic anaemia 2.1% , ITP 1.0%, liver disorders1.0%, neurosurgical0.9%, active bleeding 0.8%, miscellaneous 0.7% and vitiligo-0.5%. An average increment of platelets in the patients was 36.13x103 ± SD9.35x103/cumm. Out of 1120 transfusions, therapeutic were 1029(85.75%) where as prophylactic were 91(14.25%) (p=0.000003). Rationality of transfusions was 84% (p=0.000003). Adverse events during the Plateletpheresis procedures was 0.8% (p=0.000004).
Conclusions: A better rationality of SDP 84% in the study was observed. SDP should be used rationally and scientifically as per proven criteria because it has no alternative.
Keywords: Plateletpheresis, Single Donor Platelets, Donor, Rationality.
References
1. T.L. Simon, W.H. Dzik, E.L. Synder, et al. Rossi’s principles of transfusion medicine.
2. M.F. Murphy, D.H. Pamphilon Practical transfusion medicine. Willey-Blackwell, Oxford (2009) p. 421–429
3. M.E. Brecher AABB Technical Manual Maryland AABB’s Premier Publication (2005)
4. Mohanty, D. (2009). Current concepts in platelet transfusion. Asian Journal of Transfusion Science, 3(1), 18–21
5. Wandt H, Ehninger G, Gallmeier WM. New strategies for prophylactic platelet transfusion in patients with hematologic diseases. Oncologist 2001; 6(5):446-50.
6. Blajchman MA, Slichter SJ, Heddle NM, Murphy MF. New strategies for the opti-mal use of platelet transfusions. Hemato-logy Am Soc Hematol Educ Program. 2008:198-204. doi: 10.1182/asheducation-2008.1.198.
7. Shankar R Raikar, Panna K Kamdar, Ajay S Dabhi, Clinical and Laboratory Evaluation of Patients with Fever with Thrombocytopenia, Indian Journal of Clinical Practice, Vol. 24, No. 4, September 2013.
8. David J. Kuter, MD, dphil Managing Thrombocytopenia Associated With Cancer chemotherapy review Article | April 15, 2015 | Oncology Journal, Cancer Complications.
9. British Committee for Standards in Haematology Guidelines for platelet transfusions. Transfusion Medicine, 2, (1992) 311–318.
10. Richard M. Kaufman. Platelet Transfusion: A Clinical Practice Guideline from the AABB. Ann Intern Med. 2015; 162(3):205-213. doi:10.7326/M14-1589.
11. Ravindra P. Singh, Neelam Marwaha, Pankaj Malhotra and Sumitra Dash, Quality assessment of platelet concentrates prepared by platelet rich plasma-platelet concentrate, buffy coat poor-platelet conc-entrate (BC-PC) and apheresis-PC methods Asian J Transfus Sci. 2009 Jul; 3(2): 86–94.doi: 10.4103/0973-6247.53882.
12. Ness P et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41:857-61.
13. Ness PM1, Campbell-Lee SA. Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol. 2001 Nov;8(6):392-6. DOI: 10.1097/00062752-200111000-00013
14. Platelet Transfusion in Clinical Practice: Professional Guidance Document Review date January 2014 Version 1.0 (January 2012).
15. NAC O. Standards for Blood Banks & Blood Transfusion Services. National AIDS Control Organization Ministry of Health and Family Welfare Government of India New Delhi ; 29.08 2007 . http://naco.gov.in/blood-transfusion-services-publications
16. Saluja K, Thakral B, Marwaha N, Sharma RR. Platelet audit: Assessment and utilization of this precious resource from a tertiary care hospital. 2007;1(1):8-11.
17. Dharmesh Chandra Sharma, Lokesh Tripathi, Poonam Woike, Sunita Rai and Rajesh Gaur. Audit of Platelets Usage among Patients: A Descriptive Study of Various Platelet Concentrates. International Blood Research & Reviews 6(4):1-9, 2016, Article no.IBRR.29327 DOI : 10.9734/IBRR/2016/29327
18. Chaurasia R., Zaman S, Chatterjee K, Das B. Retrospective review of platelettrans fusion practices during 2013 Dengue Epidemic of Delhi, India; Transfus Med Hemother. 2015;42:227–23.
19. Amanat ST, Shakoor HA, Raza M, Khan N, Rauf A Clinical Indications and Adverse Reactions of Platelet Apheresis. J Coll Physicians Surg Pak. 2015 Jun; 25(6):403-6. doi: 06.2015/JCPSP.403406.
20. McCullough J. Overview of platelet transfusion. Semin Hematol 2010; 47:235.
21. Dharmesh Chandra Sharma, Sunita Rai, Sudha Iyenger, Bharat Jain, Satya Sao “Prevalence and Distribution of ABO and Rh-D Antigens along with Its Subgroups & Rare Types in Greater Gwalior Region” Open Journal of Blood Diseases, 2013, 3(2), 69-73. DOI: 10.4236/ojbd.2013.32015 http://www.scirp.org/journal/ojbd/
22. Maria Rosaria De Pascale1, Linda Sommese1, Amelia Casamassimi , Claudio Napoli. Platelet Derivatives in Regenerative Medicine: An Update Transfusion Medicine Reviews Volume 29, Issue 1, January 2015, Pages 52–61
23. Singh R P · Neelam Marwaha · Pankaj Malhotra · Sumitra Dash. Therapeutic efficacy of different types of platelet concentrates in thrombocytopenic patients. Indian J. Hematol. Blood Transfus 24(1): 16–22.
24. Buhrkuhl DC1, Karlsson MK, Carter JM; An audit of platelet transfusion within the Wellington Cancer Centre; Intern Med J. 2012 Jan;42(1):65-70. doi: 10.1111/j.1445-5994.2010.02358.x.
25. Davidson A ; Brief Audit of Platelet Use in the Yorkshire and The Humber Region , Yorkshire and The Humber Regional Transfusion Committee;2014
26. Qureshi H, Phil Dobson, Derek Lowe, John Grant-Casey, David Dalton, Kathleen Hickling, Fiona Waller. Audit of the Use of Platelets; National Comparative Audit of Blood Transfusion; St. Elsewhere s NHS Foundation Trust; March 2003.
27. Hui CH, Williams I, Davis K.; Clinical audit of the use of fresh-frozen plasma and platelets in a tertiary teaching hospital and the impact of a new transfusion request form; Intern Med J.2005 May;35(5):283-8.
28. Minal Wade · Ratna Sharma · Mamta Manglani; Rational use of blood compo-nents – an audit; Indian J Hematol Blood Transfus 25(2):66–69.
29. Charlewood R 2007, Platelet usage in Seven New Zealand Hospitals; A Final Report.
30. Pietro Bonomo, and Giuseppe Aprili Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus. 2009 Jan; 7(1): 35–38. doi: 10.2450/2008.0018-08 PMCID: PMC2652234
31. Barbosa M H, Nunes da Silva K F, Coelho D Q, Tavares J L, Cruz L F and Kanda M H: Risk factors associated with the occurrence of adverse events in plateletpheresis donation Rev Bras Hematol Hemoter. 2014 May-Jun; 36(3): 191–195. Published online 2014 Apr 3. doi: 10.1016/j.bjhh.2014.03.008 PMCID: PMC4109738.
32. Gopal Kumar Patidar, Ratti Ram Sharma and Neelam Marwaha frequency of adverse events in plateletpheresis donors in regional transfusion centre in North India. Transfusion and Apheresis science Oct 2013Vol 49, Issue 2, Pages 244–248.
DOI: https://dx.doi.org/10.18535/jmscr/v5i2.60
